The PR is somewhat confusing. I’m glad for the update but CYDY needs to do a better job of writing these PRs. They need to put a table or two in these PRs for the data so we can better understand all the different percentages. Etc, especially for total failure rate at each dosage, etc. And in what sense did Leronlimab exceed expectations? Is it the 90% response wait after 10 weeks? Sounds great but that doesn’t equal an overall 90% success rate when considering the total number of failures up to that point?

The interesting part of this PR is the deal with IncellDX. Yes, this could extend the trial further but this type of precision medicine is the future. There’s a lot of talk about the use of this precision medicine to properly treat Alzheimer’s patients and other disrorders. Initial studies look very promising and could better help biotechs identify the optimal dose rate for indiviual patients, making success rates higher as long as doses are within the safe range. I just hope this doesn’t draw out the trial because it kind of sounds that way.